151 related articles for article (PubMed ID: 21403667)
1. Hematology: Rituximab for follicular lymphoma: maintaining an open mind.
Cheson BD
Nat Rev Clin Oncol; 2011 May; 8(5):257-8. PubMed ID: 21403667
[No Abstract] [Full Text] [Related]
2. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.
Jones B
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 23999211
[No Abstract] [Full Text] [Related]
3. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
4. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
5. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.
Nabhan C; Smith SM; Kahl BS
Leuk Lymphoma; 2012 May; 53(5):770-8. PubMed ID: 21958083
[TBL] [Abstract][Full Text] [Related]
6. Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
Croxtall JD
BioDrugs; 2011 Oct; 25(5):329-31. PubMed ID: 21942917
[No Abstract] [Full Text] [Related]
7. Chemotherapy: maintenance rituximab for relapsed follicular lymphoma.
Wrench D; Montoto S
Nat Rev Clin Oncol; 2010 Dec; 7(12):677-8. PubMed ID: 21116237
[No Abstract] [Full Text] [Related]
8. Follicular lymphoma: watch and wait is watch and worry.
Ansell SM
Lancet Oncol; 2014 Apr; 15(4):368-9. PubMed ID: 24602759
[No Abstract] [Full Text] [Related]
9. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
10. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.
Sarkozy C; Seymour JF; Ferme C; Caballero D; Ghesquieres H; Leppa S; Delarue R; Pedersen LM; Mounier C; Gomes Da Silva M; Chassagne-Clement C; Maerevoet M; Salles G
Blood; 2014 Apr; 123(17):2740-2. PubMed ID: 24764560
[No Abstract] [Full Text] [Related]
11. Rituximab maintenance therapy for follicular lymphoma.
Haines I
Lancet; 2011 Apr; 377(9772):1151; author reply 1151-2. PubMed ID: 21459205
[No Abstract] [Full Text] [Related]
12. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).
Lee CS; Ashton-Key M; Cogliatti S; Rondeau S; Schmitz SF; Ghielmini M; Cragg MS; Johnson P
Br J Haematol; 2015 Jan; 168(1):145-8. PubMed ID: 25142001
[No Abstract] [Full Text] [Related]
13. Current and future management of follicular lymphoma.
Salles G; Ghesquières H
Int J Hematol; 2012 Nov; 96(5):544-51. PubMed ID: 23108535
[TBL] [Abstract][Full Text] [Related]
14. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660
[TBL] [Abstract][Full Text] [Related]
15. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?
LeBlanc T; Kamal A; Abernethy A
Lancet Oncol; 2014 Jun; 15(7):e251-2. PubMed ID: 24872108
[No Abstract] [Full Text] [Related]
17. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O
J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664
[TBL] [Abstract][Full Text] [Related]
18. NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.
Doss S; Garrett Z; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Feb; 13(2):128-30. PubMed ID: 22403811
[No Abstract] [Full Text] [Related]
19. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
[TBL] [Abstract][Full Text] [Related]
20. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.
Keegan TH; Moy LM; Foran JM; Alizadeh AA; Chang ET; Shema SJ; Schupp CW; Clarke CA; Glaser SL
Leuk Lymphoma; 2013 Apr; 54(4):743-51. PubMed ID: 22957852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
